Allergy Thera. Share News (AGY)
AGY Share
AGY Share
AGY Share
AGY Share
AGY
AGY Share
AGY Level 2
AGY Live
AGY Broker
AGY Directors
AGY Financial
AGY
AGY Short
AGY
Last checked at -
Fri, 08th Jul 2016 14:02
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.
Read more(Alliance News) - Allergy Therapeutics PLC on Tuesday said it has commenced subcutaneous dosing of peanut allergic patients in its phase 1/2a Protect trial.
Read more| Monday 4 March | |
| Ascent Resources PLC | GM re bonus issue of preference shares |
| JPMorgan Emerging Europe, Middle East & Africa Securities PLC | AGM |
| Lexington Gold Ltd | AGM |
| Tuesday 5 March | |
| Ajax Resources PLC | GM re extension of investment mandate |
| Beowulf Mining PLC | GM re capital raise |
| CC Japan Income & Growth Trust PLC | AGM |
| Driver Group PLC | AGM |
| Edinburgh Worldwide Investment Trust PLC | AGM |
| Jersey Electricity PLC | AGM |
| Wednesday 6 March | |
| Ecofin Global Utilities & Infrastructure Trust PLC | AGM |
| Mila Resources PLC | AGM |
| Paragon Banking Group PLC | AGM |
| Thursday 7 March | |
| Asia Strategic Holdings Ltd | AGM |
| CT UK Capital & Income Investment Trust PLC | AGM |
| Henderson Opportunities Trust PLC | AGM |
| XPS Pensions Group PLC | GM re directors' remuneration policy 2024 |
| Friday 8 March | |
| Allergy Therapeutics PLC | AGM |
| All Things Considered Group PLC | AGM |
| Chenavari Toro Income Fund Ltd | AGM |
| Neo Energy Metals PLC | AGM |
| Schroder UK Mid Cap Fund PLC | AGM |
| Silverwood Brands PLC | GM re proposed share capital reduction |
| Comments and questions to newsroom@alliancenews.com | |
| A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
| Copyright 2024 Alliance News Ltd. All Rights Reserved. | |
(Alliance News) - Allergy Therapeutics PLC on Wednesday said revenue decreased in its latest half year, and expects to require further funding soon.
Read more(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Read more(Alliance News) - Allergy Therapeutics PLC on Tuesday resumed trading on AIM after the release of its annual results.
Read moreAllergy Therapeutics PLC - Sussex-based biotechnology company specialising in allergy vaccines - Shares rise as firm enters amendment to the facility agreement it reached in early April with SkyGem Acquisition Ltd and Southern Fox Investments Ltd. Deal provides Allergy Therapeutics with a GBP40 million secured loan facility of which GBP32.5 million is uncommitted. Facility is available to drawdown between January 15 and the same day in 2026, with interest payable semi-annually at 12% per year and a January 15, 2027 repayment date.
Read more(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:
Read more(Alliance News) - Allergy Therapeutics PLC on Wednesday said that phase-3 trials of its grass allergy injection yielded positive results, moving the product closer to market entry.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.
Read more(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.
Read more(Alliance News) - Allergy Therapeutics PLC on Tuesday said that a trial evaluating the efficacy of its subcutaneous allergen-specific immunotherapy candidate has met its primary endpoint.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.
Read moreAllergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says it continued to work on initiatives to improve cost control and manage working capital alongside trading broadly in line with expectations for the current financial year to date. Says it has extended its cash runway and anticipates to require additional funding by the end of December. Further, says discussions with some major shareholders regarding a subscription and open offer announced in October have progressed. Says that the pivotal phase 3 grass G306 modified allergen tyrosine adsorbed monophosphoryl lipid A trial remains on track to report interim results this month. Via G306, the company aims to release an immunotherapy for grass allergy.
Read more
Last checked at